Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents.

Creator(s)

Ravi Jhaveri
Felice C. Adler-Shohet
Christopher C. Blyth
Kathleen Chiotos
Jeffrey S. Gerber
Michael Green
Larry Kociolek
Rachel Martin-Blais
Debra Palazzi
Andi L. Shane
Jennifer E. Schuster, Children's Mercy HospitalFollow
Stanford T. Shulman
Gregory A. Storch
Geoffrey A. Weinberg
Theoklis Zaoutis

Document Type

Article

Publication Date

11-11-2021

Identifier

DOI: 10.1093/jpids/piab061; PMCID: PMC8344506

Journal Title

J Pediatric Infect Dis Soc

Volume

10

Issue

10

First Page

937

Last Page

939

MeSH Keywords

Adolescent; COVID-19; Humans; RNA, Messenger; SARS-CoV-2; Vaccination

Keywords

Adolescent; COVID-19; Humans; RNA, Messenger; SARS-CoV-2; Vaccination

Recommended Citation

Jhaveri R, Adler-Shohet FC, Blyth CC, et al. Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc. 2021;10(10):937-939. doi:10.1093/jpids/piab061